A double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS

@article{Holodniy1999ADB,
  title={A double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS},
  author={Mark Holodniy and Johannes Koch and Mark Mistal and Jamey M Schmidt and Atul S. Khandwala and James E. Pennington and Steven B. Porter},
  journal={American Journal of Gastroenterology},
  year={1999},
  volume={94},
  pages={3267-3273}
}
Objective:The aim of this study was to investigate the safety and effectiveness of orally administered SP-303 in patients with AIDS and diarrhea.Methods:This is a multicenter, phase II, randomized, double blind, placebo-controlled study. HIV-positive subjects with a history of a CD4 count <200 or an AIDS-defining illness were admitted to an inpatient study unit and screened for diarrhea defined as at least three abnormal (i.e., soft or watery) stools and >200 g of abnormal stool weight over a… 

Figures and Tables from this paper

Efficacy and Safety of Crofelemer for Noninfectious Diarrhea in HIV-Seropositive Individuals (ADVENT Trial): A Randomized, Double-Blind, Placebo-Controlled, Two-Stage Study
TLDR
In HIV-seropositive patients taking stable antiretroviral therapy, crofelemer provided significant improvement in diarrhea with a favorable safety profile and was minimally absorbed, well tolerated, did not negatively impact clinical immune parameters, and had a safety profile comparable to placebo.
The effect of dairy product ingestion on human immunodeficiency virus-related diarrhea in a sample of predominantly gay men: a randomized, controlled, double-blind, crossover trial.
TLDR
Moderate lactose ingestion does not worsen diarrhea in HIV-infected persons with chronic diarrhea, regardless of lactase status, and avoidance of modest quantities of milk may not be justified in this population.
Systematic Review of Strategies to Measure HIV-Related Diarrhea
TLDR
An easy-to-use, well-accepted, and valid tool to measure HIV-related diarrhea would enhance research in this field and reduce the reliance on nonvalidated and disparate measures.
Preclinical and Clinical Safety and Efficacy of Faramir Treatment: A Novel Anti-Retroviral Drug
TLDR
Some evidence was found in support of the efficacy and safety of Faramir and implementation of phase III clinical trial is recommended.
Crofelemer: A Review of its Use in the Management of Non-Infectious Diarrhoea in Adult Patients with HIV/AIDS on Antiretroviral Therapy
TLDR
Crofelemer is the first (and so far only) agent to be approved by the US FDA specifically for the symptomatic relief of non-infectious (i.e. secretory) diarrhoea in adult patients with HIV/AIDS on antiretroviral therapy (ART).
Noninfectious Diarrhea in HIV Seropositive Individuals: a Review of Prevalence Rates, Etiology, and Management in the Era of Combination Antiretroviral Therapy
TLDR
Approaching management using a stepwise method of nonpharmacologic (diet), nonprescription (over-the-counter) and prescription agent changes (modification of cART or addition of an evidence-based antidiarrheal) appears reasonable, despite a lack of clear scientific evidence to support the initial two steps of this approach.
Evaluation of Crofelemer in the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome Patients
TLDR
Crofelelmer did not produce benefit on bowel function; an increase in the number of pain- and discomfort-free days in female D-IBS patients was seen; further studies with crofelemer are warranted to evaluate it as a potential visceral analgesic.
Practical Considerations for a Two-Stage Confirmatory Adaptive Clinical Trial Design and Its Implementation: ADVENT Trial
TLDR
This trial was conducted as a “final phase 3” clinical trial to establish the safety and efficacy of a first-in-class antidiarrheal agent, crofelemer, for the symptomatic relief of diarrhea in HIV patients receiving anti-retroviral therapy.
Crofelemer, a Novel Agent for Treatment of Secretory Diarrhea
TLDR
Oral crofelemer possesses a novel mechanism of action that shows promise in treating secretory diarrhea of several etiologies, however, results from further Phase 3 clinical trials are still needed in order to fully evaluate the efficacy and safety of this agent.
Emerging drug for diarrhea predominant irritable bowel syndrome
Introduction: Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders with a 9 – 23% prevalence estimated in the general population. Patients can be subdivided into those
...
...

References

SHOWING 1-10 OF 42 REFERENCES
Improvement of chronic diarrhoea in patients with advanced HIV‐1 infection during potent antiretroviral therapy
TLDR
The use of potent antiretroviral therapy in patients with advanced HIV infection can improve chronic HIV-related diarrhoea and in some cases lead to disappearance of E. bieneusi and Cryptosporidium sp.
Mechanism and treatment of diarrhoea due to Vibrio cholerae and Escherichia coli: roles of drugs and prostaglandins.
TLDR
It is concluded that CPZ, berberine, and nicotinic acid are potential antidiarrhoeal agents, tetracycline and furazolidone are effective antimicrobial agents in cholera, and glucose short-chain polymers are better sources of carbohydrates in oral rehydration solutions.
Mechanism and treatment of diarrhoea due to Vibrio cholerae and Escherichia coli: roles of drugs and prostaglandins.
  • G. Rabbani
  • Medicine, Biology
    Danish medical bulletin
  • 1996
TLDR
CPZ, berberine, and nicotinic acid are potential antidiarrhoeal agents, tetracycline and furazolidone are effective antimicrobial agents in cholera, and glucose short-chain polymers are better sources of carbohydrates in oral rehydration solutions.
Natural history and prognosis of diarrhoea of unknown cause in patients with acquired immunodeficiency syndrome (AIDS).
TLDR
Patients with advanced human immunodeficiency virus infection and chronic diarrhoea for which no cause could be found after extensive investigations, including examination of multiple stool specimens for all known faecal pathogens and the histological examination of small and large bowel biopsy specimens are recruited.
Quality of life and health service use among HIV-infected patients with chronic diarrhea.
TLDR
It is suggested that HIV-infected patients with diarrhea experience marked decreases in quality of life and that care for patients with chronic diarrhea is costly.
Elevated plasma levels of vasoactive intestinal peptide in AIDS patients with refractory idiopathic diarrhoea. Effects of treatment with octreotide
TLDR
The data on the association of idiopathic secretory diarrhoea and elevated plasma VIP levels provide a possible pathophysiological rationale for identifying AIDS patients whose refractory diarrhea may be more responsive to octreotide treatment.
HIV-associated diarrhoea and wasting
Human immunodeficiency virus type 1 protease inhibitors.
TLDR
Four protease inhibitors, saquinavir mesylate, ritonavir, nelfinavir, and indinavir sulfate, have been approved by the Food and Drug Administration and other agents are undergoing active investigation.
...
...